The popularity of Sildenafil initially drove a surge for pharma, nevertheless recent shifts knockoff present a complicated outlook for shareholders. Off-patent versions are eating into profits, and continued litigation add more risk to the landscape. While certain companies might still gain from related offerings, the broader trajectory suggests a